Anastasia A.
- Country
- Greece
- Department
- 4th University Department of Internal Medicine
Research Overview
- Evaluation of Abatacept and Placebo in Hospitalized Adults with COVID-19: A Randomized, Controlled Trial on Immune Modulation Strategies
- Phase 3 Randomized Study of Echinocandin Followed by Ibrexafungerp vs. Echinocandin Followed by Fluconazole in Invasive Candidiasis/Candidemia
- Evaluation of Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin Efficacy and Safety in Early-Stage COVID-19 Adult Outpatients: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 23 of 67 partner sites.
Specializations
Infectious Disease Management
The investigator specializes in treating invasive fungal infections, particularly focusing on innovative therapeutic approaches for candidemia and invasive candidiasis. Their research explores alternative treatment pathways using both intravenous and oral antifungal medications.
- Systemic Fungal Infections
- Antifungal Therapy Optimization
- Treatment Transition Strategies
COVID-19 Therapeutics
The investigator leads research in COVID-19 treatment modalities, with particular emphasis on outpatient management and immunological interventions. Their work encompasses both early-stage treatment and advanced therapeutic strategies for hospitalized patients.
- Immunoglobulin Therapy
- Antiviral Treatments
- Standard of Care Optimization
Respiratory Infection Platforms
The investigator develops comprehensive approaches to acute respiratory infections, focusing on therapeutic interventions and treatment strategies for hospitalized adults. Their research includes evaluation of protease inhibitors and immune modulation techniques.
- Clinical Trial Platforms
- Therapeutic Strategy Development
- Immune Response Modification
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.